Isis Pharma (ISIS) Tops Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Isis Pharma (ISIS) Remains Overbought Following Recent Run
March 2, 2015 3:14 PM ESTIsis Pharma (Nasdaq: ISIS) is largely in overbought territory as the stock's recent run is coming to a halt.
Market data has the 14-day money flow index at 81.4 percent, above the 80 percent overbought threshold. Overall, money flow is negative $3.1 million in afternoon trading for an... More
Stifel Downgrades ISIS Pharmaceuticals (ISIS) to Hold
March 2, 2015 6:35 AM ESTStifel downgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Buy to Hold and removed its price target (prior $66.00).
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $68.56 yesterday.
... More